Fulcrum Therapeutics is cutting its staff from 57 to 9 as the biotech seeks a merger or acquisition after ending its sickle ...
Most corporate sponsors are returning, including Fidelity Investments, as some new companies join and some exit Boston’s ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する